A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients. (July 2016)

• Record Type: Journal Article
• Authors: Gui, Yu; Xu, Shuman; Yang, Xi; Gu, Lu; Zhang, Ze; Luo, Xiangdong; Chen, Li
• Is Part Of: Biomarkers in medicine. Volume 10:Number 7(2016)
• Page Start: 771
• Page End: 790
• Publication Date: 2016-07
• Subjects: biomarkers -- chemotherapy -- meta-analysis -- prognosis -- triple-negative breast cancer; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2015-0064
• Languages: English
• ISSNs: 1752-0363

Abstract

Identification of biomarkers that has the ability to predict triple-negative breast cancer (TNBC) prognosis especially in patients undergoing chemotherapy is very important.Methods: The cohort studies that reported association between chemotherapy biomarker expression and survival outcome in TNBC patients were included in our analysis.Results: The promising markers that emerged for the prediction of disease-free survival and overall survival included Ki67, BRCA1 methylation and LC3B. Furthermore, Ki67 appeared to be also significantly associated with worse disease-free survival in TNBC patients who received anthracycline-based chemotherapy.Conclusion: This meta-analysis demonstrated that in TNBC patients receiving chemotherapy, Ki67 is a predictor for poor prognosis, BRCA1 methylation and LC3B are also potential prognostic markers. In addition, the TNBC patients with high Ki67 expression seems to display resistance to anthracycline-based chemotherapy.